Trial · NCT07913763
Rimonabant for Improving Walking Ability in Patients With Chronic Stroke
NCT07913763, Phase 2, Not yet recruiting, Sinfatin S.L
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rimonabant for Improving Walking Ability in Patients With Chronic Stroke. Trials, record NCT07913763. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913763
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rimonabant for Improving Walking Ability in Patients With Chronic Stroke
- NCT number
- NCT07913763
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Sinfatin S.L
- Conditions
- Chronic Stroke
- Interventions
- Rimonabant, Placebo
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Six-Minute Walk Test (6MWT) | Baseline to end of follow-up (day 135) | The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The primary endpoint is the percentage change in walking distance from baseline to the end of follow-up on day 135. Greater distances indicate better walking capacity. |
| Secondary | Six-Minute Walk Test (6MWT) -EOT | Baseline to end of treatment (day 90) | The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The percentage change in walking distance from baseline to the end of treatment at day 90. Greater distances indicate better walking capacity. |
| Secondary | Borg CR10 Scale | Baseline to end of follow-up (day 135) | The Borg CR10 Scale assesses perceived exertion after the 6MWT. Scores range from 0 (no exertion) to 10 (maximal exertion). Higher scores indicate greater perceived exertion. |
| Secondary | 6MWT Clinically Relevant Improvement | Baseline to end of follow-up (day 135) | The number of participants achieving a clinically relevant improvement in walking distance, defined as an increase of more than 40 meters or more than 25% compared with baseline. |
| Secondary | Ten-Meter Walk Test (10MWT) | Baseline to end of follow-up (day 135) | The Ten-Meter Walk Test (10MWT) assesses walking performance by measuring the time required to walk 10 meters at a comfortable or maximal pace. Shorter completion times indicate faster walking performance. Walking speed over 10 meters is reported in meters/second. |
| Secondary | Multidimensional Fatigue Inventory (MFI-20) | Baseline to end of follow-up (day 135) | The MFI-20 assesses fatigue across five dimensions using 20 items. The total score ranges from 20 to 100, with higher scores indicating greater fatigue. |
| Secondary | Fatigue Severity Scale (FSS) | Baseline to end of follow-up (day 135) | The FSS assesses the impact of fatigue on daily functioning. It contains nine items scored from 1 to 7. The mean score is calculated, with higher scores indicating greater fatigue severity. |
| Secondary | Stroke Impact Scale (SIS 3.0) | Baseline to end of follow-up (day 135) | The SIS 3.0 assesses the impact of stroke on health and daily functioning across multiple domains. Domain scores range from 0 to 100, with higher scores indicating better functioning or fewer limitations. |
| Secondary | Five-level EuroQol five-dimension questionnaire (EQ-5D-5L) | Baseline and end of follow-up (day 135) | The EQ-5D-5L assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a health utility index using an appropriate value set. |
| Secondary | Patient Global Impression of Change (PGIC) | End of treatment (day 90) and End of follow-up (day 135). | The PGIC assesses the participant's overall perception of change in their condition. Scores range from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913763
GET https://conductscience.org/api/trials/v1/NCT07913763/registered